These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 16467018

  • 1. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.
    Gordon KB, Gottlieb AB, Leonardi CL, Elewski BE, Wang A, Jahreis A, Zitnik R.
    J Dermatolog Treat; 2006; 17(1):9-17. PubMed ID: 16467018
    [Abstract] [Full Text] [Related]

  • 2. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L, Etanercept Psoriasis Study Group.
    Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
    [Abstract] [Full Text] [Related]

  • 3. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J.
    Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
    [Abstract] [Full Text] [Related]

  • 4. Intermittent etanercept therapy in pediatric patients with psoriasis.
    Siegfried EC, Eichenfield LF, Paller AS, Pariser D, Creamer K, Kricorian G.
    J Am Acad Dermatol; 2010 Nov; 63(5):769-74. PubMed ID: 20833444
    [Abstract] [Full Text] [Related]

  • 5. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice.
    Barrera MV, Habicheyn S, Mendiola MV, Herrera Ceballos E.
    Eur J Dermatol; 2008 Nov; 18(6):683-7. PubMed ID: 19049936
    [Abstract] [Full Text] [Related]

  • 6. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A.
    Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
    [Abstract] [Full Text] [Related]

  • 7. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.
    Elewski B, Leonardi C, Gottlieb AB, Strober BE, Simiens MA, Dunn M, Jahreis A.
    Br J Dermatol; 2007 Jan; 156(1):138-42. PubMed ID: 17199580
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
    Gisondi P, Del Giglio M, Cotena C, Girolomoni G.
    Br J Dermatol; 2008 Jun; 158(6):1345-9. PubMed ID: 18410408
    [Abstract] [Full Text] [Related]

  • 10. Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial.
    Krueger GG, Elewski B, Papp K, Wang A, Zitnik R, Jahreis A.
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S112-9. PubMed ID: 16488321
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
    Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, Chang T.
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
    [Abstract] [Full Text] [Related]

  • 12. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes.
    Kircik L, Bagel J, Korman N, Menter A, Elmets CA, Koo J, Yang YC, Chiou CF, Dann F, Stevens SR, Unite Study Group.
    J Drugs Dermatol; 2008 Mar; 7(3):245-53. PubMed ID: 18380206
    [Abstract] [Full Text] [Related]

  • 13. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
    Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, Stevens SR.
    J Am Acad Dermatol; 2007 Apr; 56(4):598-603. PubMed ID: 17113190
    [Abstract] [Full Text] [Related]

  • 14. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.
    Reich K, Segaert S, Van de Kerkhof P, Durian C, Boussuge MP, Paolozzi L, Wajdula J, Boggs R.
    Dermatology; 2009 Apr; 219(3):239-49. PubMed ID: 19752505
    [Abstract] [Full Text] [Related]

  • 15. Etanercept treatment for children and adolescents with plaque psoriasis.
    Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, Hebert AA, Eichenfield LF, Patel V, Creamer K, Jahreis A, Etanercept Pediatric Psoriasis Study Group.
    N Engl J Med; 2008 Jan 17; 358(3):241-51. PubMed ID: 18199863
    [Abstract] [Full Text] [Related]

  • 16. Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study).
    Cassano N, Loconsole F, Galluccio A, Miracapillo A, Pezza M, Vena GA.
    Int J Immunopathol Pharmacol; 2006 Jan 17; 19(1):225-9. PubMed ID: 16569361
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Two years of experience with etanercept in recalcitrant psoriasis.
    Ahmad K, Rogers S.
    Br J Dermatol; 2007 May 17; 156(5):1010-4. PubMed ID: 17408393
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A randomized trial of etanercept as monotherapy for psoriasis.
    Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R.
    Arch Dermatol; 2003 Dec 17; 139(12):1627-32; discussion 1632. PubMed ID: 14676082
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.